Trending...
- Charmaine Thompson Turns Pain Into Purpose Through Woman of Power Charmcare
- Ritz-Carlton Residences Houston Generates Strong Early New Construction Sales at 2120 Post Oak Blvd
- FDA Path Clears, Manufacturing Ramps Up + $22.3 Million Strengthens the Balance Sheet; Inflection Point for NRx Pharmaceuticals (N A S D A Q: NRXP)
WEST CHESTER, Pa.--(BUSINESS WIRE)--Beth Altman, former managing partner at accounting firm KPMG LLP San Diego, has joined Papyrus Therapeutics Inc. as an independent director of the Company's Board of Directors and as Chair of the Audit Committee.
Beth has more than 27 years of experience in accounting, finance, management, business development, strategic planning and corporate governance. During her 25-year career at KPMG LLP, Altman led a team of more than 260 professionals to provide assurance, tax and advisory services to public and private companies spanning all industry sectors. She also served as the lead audit partner for numerous public and private companies, predominantly in the life sciences and technology sectors. Since her retirement from KPMG LLP in October 2019, she has served on the Board and the Audit Committee of Allscripts Healthcare Inc., and Alphatec Holdings, Inc. and she has served on the Board and as Chair of the Audit Committee of CV Sciences, Inc.
She previously served as a board member of the Corporate Directors Forum, a 501 (c)(6) nonprofit organization focused on helping directors build more effective boards and held a leadership position in the Women Corporate Directors, San Diego Chapter, the world's largest membership organization and community of today's preeminent women leaders in business.
More on The PennZone
CEO Dr Paul Blake stated, "I am delighted that Beth is joining Papyrus Therapeutics. She has a deep experience of business, accounting, and finance, which coupled with her experience on the boards of other life science companies, will be of indispensable value to us as we expand our activities."
About Papyrus Therapeutics Inc.: Papyrus Therapeutics, Inc. (West Chester, PA, USA) is an emerging biopharma company developing novel tumor suppressor-based therapies. Papyrus´ lead therapeutic is a modified, recombinant version of Opioid Binding Protein/Cell Adhesion Molecule-like (OPCML). OPCML is a broadly acting tumor suppressor that is epigenetically silenced in many cancers, leading to tumor invasion and metastasis through deregulation of apoptosis, epithelial-to-mesenchymal transition (EMT) and cellular migration. Classic receptor tyrosine kinase [RTK] inhibition using small molecules has proven highly effective in many cancers, but treatment resistance remains a significant challenge. Delivery of OPCML, which works at the cell surface, can overcome this challenge by reconstituting normal RTK signaling in the tumor.
Contacts
Media
Dr Paul Blake
908 330 6997
pblake@pytxi.com
Beth has more than 27 years of experience in accounting, finance, management, business development, strategic planning and corporate governance. During her 25-year career at KPMG LLP, Altman led a team of more than 260 professionals to provide assurance, tax and advisory services to public and private companies spanning all industry sectors. She also served as the lead audit partner for numerous public and private companies, predominantly in the life sciences and technology sectors. Since her retirement from KPMG LLP in October 2019, she has served on the Board and the Audit Committee of Allscripts Healthcare Inc., and Alphatec Holdings, Inc. and she has served on the Board and as Chair of the Audit Committee of CV Sciences, Inc.
She previously served as a board member of the Corporate Directors Forum, a 501 (c)(6) nonprofit organization focused on helping directors build more effective boards and held a leadership position in the Women Corporate Directors, San Diego Chapter, the world's largest membership organization and community of today's preeminent women leaders in business.
More on The PennZone
- Obsolete Industrial Expands Its Membership
- FindCostSeg Launches Nationwide Directory for Cost Segregation Providers
- Master Of Science, Juggernaut Of The Screen: Landon Brittain Emerges As Hollywood's Most Unlikely Leading Man
- Black Dog Venture Partners and VC Fast Pitch to Host "San Francisco Investors and Innovators" Networking Event
- Four-Time Olympian Joetta Clark Diggs to Compete at World Masters Athletics Championships in Daegu
CEO Dr Paul Blake stated, "I am delighted that Beth is joining Papyrus Therapeutics. She has a deep experience of business, accounting, and finance, which coupled with her experience on the boards of other life science companies, will be of indispensable value to us as we expand our activities."
About Papyrus Therapeutics Inc.: Papyrus Therapeutics, Inc. (West Chester, PA, USA) is an emerging biopharma company developing novel tumor suppressor-based therapies. Papyrus´ lead therapeutic is a modified, recombinant version of Opioid Binding Protein/Cell Adhesion Molecule-like (OPCML). OPCML is a broadly acting tumor suppressor that is epigenetically silenced in many cancers, leading to tumor invasion and metastasis through deregulation of apoptosis, epithelial-to-mesenchymal transition (EMT) and cellular migration. Classic receptor tyrosine kinase [RTK] inhibition using small molecules has proven highly effective in many cancers, but treatment resistance remains a significant challenge. Delivery of OPCML, which works at the cell surface, can overcome this challenge by reconstituting normal RTK signaling in the tumor.
Contacts
Media
Dr Paul Blake
908 330 6997
pblake@pytxi.com
0 Comments
Latest on The PennZone
- Kellyn Endorses National Push to Expand Food is Medicine
- LATO AI Automates Customer Communication to Help CSide Sports Academy and BAT 24 Nation Grow
- Real Estate Syndication Attorney Tilden Moschetti Releases The Real Estate Private Equity Blueprint
- 5X Gross Margin Improvement to Beat EPS Consensus; $54.6 Million 10-Year Contract Award Puts Cybersecurity Leader on Path to a $30 Million Run Rate
- Tina Hasselbusch, Turnstone Creative Co-founder and Chief Executive Officer, Named to LVB 300
- Pittsburgh Family Law Attorneys at Pollock Begg Earn Top Honors in 2027 Best Lawyers Guide
- Independent Colbert Packaging Thrives Amid Industrywide Consolidation
- Free Commercial Glass Estimating and Code Compliance Tools Launched by Landmark Construction - The Leading Glass Company in Los Angeles
- Tallahassee Million-Dollar Home Sales Rise in 2026 as Median Selling Time More Than Doubles
- Slotozilla Reports Strong Growth in Q2 2026
- Eric Snyder, President and Chief Executive Officer of Keystone Consulting Engineers Named to LVB 300
- Philadelphia's Girls Anthem to Host The Locker Room Experience Pop-Up for Young Women
- Flexible Plan Investments Names Carl Resnick President
- Paula Josephine Sadler Releases "Imagine" on 24th Anniversary of Sobriety
- Ritz-Carlton Residences Houston Generates Strong Early New Construction Sales at 2120 Post Oak Blvd
- No Sugar Baker Continues National Growth with Seattle Market Expansion Across Washington, Idaho, and Alaska
- The Refugee Archive Launches Campaign to Preserve 21 Female-Headed Household Oral Histories in Rebel-Controlled Goma
- Sharon Pinkenson Chosen as Philly Girl Top 40 Winner
- Space Ambitions Expanding as New Testing Builds on NASA Results and Targets MEO, GEO and Next-Generation Orbital Markets: Ascent Solar Technologies
- FDA Path Clears, Manufacturing Ramps Up + $22.3 Million Strengthens the Balance Sheet; Inflection Point for NRx Pharmaceuticals (N A S D A Q: NRXP)